drugset / Trial / NCT05268198
SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects
Phase 0
Completed
42 enrolled
Global Health Drug Discovery Institute
Avance Clinical Pty Ltd. · collabCMAX Clinical Research Pty Ltd · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of APR002 in healthy subjects.
Timeline
- Start
- 2023-03-20
- Primary completion
- 2023-06-29
- Completion
- 2023-07-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APR002 | Unknown | — | Inhaled |